Turkish Society of Cardiology Young Cardiologists
President Dr. Muzaffer Değertekin
Coordinator for the Board of Directors Dr. Ertuğrul Okuyan
Coordinator for the Board of Directors Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Preparation Göksel Çinier Ali Nazmi Çalık
|
|
|
|
Turkish Society of Cardiology Young Cardiologists Bulletin / "TSCYOUNG" Nisan 2019 (1)
Young Cardiologists Evaluate EHRA 2019 and ACC 2019
We are extremely pleased to publish the second issue of TSC Young Bulletin. The new issue includes major highlights from ACC 2019 and EHRA 2019 which were held in New Orleans and Lisbon respectively. Dr. Göksel Çinier (cinierg@gmail.com) and Dr. Ali Nazmi Çalık (calik_nazmi@hotmail.com) summarized the results of the major late breaking clinical trials from EHRA 2019 and ACC 2019 | Issue Summary | | EHRA 2019
| | | This year EHRA 2019 was held in Lisbon, Portugal. There were several important late breaking clinical trials that were presented during the Congress. Here we highlight some of them. | | | | |
| | ACC 2019
| | | Beyond any doubt, ‘PARTNER-3’ and ‘Evolut Low Risk’ trials, which compared TAVR (transcatheter aortic valve replacement) with SAVR (surgical bioprosthesis aortic valve replacement in low risk patients, had the most intriguing results. | | | | |
|